Browsing by Author "Coskun N."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Examining the protective effects of acetyl l-carnitine on cisplatin-induced uterine tube toxicity
    (Taylor and Francis Ltd, 2016) Saribas G.S.; Erdogan D.; Goktas G.; Akyol S.N.; Hirfanoglu I.M.; Gurgen S.G.; Coskun N.; Ozogul C.
    The aim of this study was to investigate the effects of cisplatin and the protective role of acetyl l-carnitine against uterine tube toxicity. Twenty-four female Wistar albino rats were divided into four groups: control group was injected with saline (control); group 2 was injected with acetyl l-carnitine; group 3 was injected with cisplatin; and group 4 was pre-treated with acetyl l-carnitine before cisplatin intraperitoneal injection. According to our results, a significant weight loss was observed in rats from group 3. The thickness of the wall and epithelium of uterine tube were decreased in group 3 rats. We elaborate the protein expression of caspase in epithelium and stroma by IHC. We found that the expression of caspase and the number of TUNEL-positive cells were increased in group 3 rats compared to the other groups. In our study, we showed the protective role of acetyl l-carnitine against uterine tube toxicity caused by cisplatin. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
  • No Thumbnail Available
    Item
    Prevalence of Childhood Affective disorders in Turkey: An epidemiological study
    (Elsevier B.V., 2018) Karacetin G.; Arman A.R.; Fis N.P.; Demirci E.; Ozmen S.; Hesapcioglu S.T.; Oztop D.; Tufan A.E.; Tural U.; Aktepe E.; Aksu H.; Ardic U.A.; Basgul S.; Bilac O.; Coskun M.; Celik G.G.; Demirkaya S.K.; Dursun O.B.; Durukan I.; Fidan T.; Gencoglan S.; Gokcen C.; Gokten E.S.; Gorker I.; Gormez V.; Gundogdu O.Y.; Gurkan C.K.; Herguner S.; Kandemir H.; Kilic B.G.; Kilincaslan A.; Mutluer T.; Nasiroglu S.; Ozcan O.O.; Ozturk M.; Sapmaz S.Y.; Suren S.; Sahin N.; Tahiroglu A.Y.; Toros F.; Unal F.; Vural P.; Yazici I.P.; Yazici K.U.; Yildirim V.; Yulaf Y.; Yuce M.; Yuksel T.; Akdemir D.; Altun H.; Ayik B.; Bilgic A.; Bozkurt O.H.; Cakir E.D.; Ceri V.; Demir N.U.; Dinc G.; Irmak M.Y.; Karaman D.; Kinik M.F.; Mazlum B.; Memik N.C.; Ozdemir D.F.; Sinir H.; Tasdelen B.I.; Taskin B.; Ugur C.; Uran P.; Uysal T.; Uneri O.S.; Yilmaz S.; Yilmaz S.S.; Acikel B.; Aktas H.; Alaca R.; Alic B.G.; Almbaidheen M.; Ari F.P.; Aslan C.; Atabay E.; Ay M.G.; Aydemir H.; Ayranci G.; Babadagi Z.; Bayar H.; Bayhan P.C.; Bayram O.; Bektas N.D.; Berberoglu K.K.; Bostan R.; Cakan Y.; Canli M.A.; Cansiz M.A.; Ceylan C.; Coskun N.; Coskun S.; Demir I.; Demir N.; Demirdogen E.Y.; Dogan B.; Donmez Y.E.; Donder F.; Efe A.; Eray S.; Erbilgin S.; Erden S.; Ersoy E.G.; Eseroglu T.; Firat S.K.; Gok E.E.; Goksoy S.C.; Guler G.; Gules Z.; Gunay G.; Gunes S.; Gunes A.; Guven G.; Horozcu H.; Irmak A.; Isik U.; Kahraman O.; Kalayci B.M.; Karaaslan U.; Karadag M.; Kilic H.T.; Kilicaslan F.; Kinay D.; Koc E.B.; Kocael O.; Mutlu R.K.; San Z.; Nalbant K.; Okumus N.; Ozbek F.; Ozdemir F.A.; Ozdemir H.; Ozgur B.G.; Ozkan S.; Ozyurt E.Y.; Polat B.; Polat H.; Sekmen E.; Sertcelik M.; Sevgen F.H.; Sevince O.; Shamkhalova U.; Suleyman F.; Simsek N.E.; Tanir Y.; Tekden M.; Temtek S.; Topal M.; Topal Z.; Turk T.; Ucar H.N.; Ucar F.; Uygun D.; Uzun N.; Vatansever Z.; Yazgili N.G.; Yildiz D.M.; Yildiz N.; Ercan E.S.
    Aim: To determine the prevalence of affective disorders in Turkey among a representative sample of Turkish population. Methods: This study was conducted as a part of the “The Epidemiology of Childhood Psychopathology in Turkey” (EPICPAT-T) Study, which was designed by the Turkish Association of Child and Adolescent Mental Health. The inclusion criterion was being a student between the second and fourth grades in the schools assigned as study centers. The assessment tools used were the K-SADS-PL, and a sociodemographic form that was designed by the authors. Impairment was assessed via a 3 point-Likert type scale independently rated by a parent and a teacher. Results: A total of 5842 participants were included in the analyses. The prevalence of affective disorders was 2.5 % without considering impairment and 1.6 % when impairment was taken into account. In our sample, the diagnosis of bipolar disorder was lacking, thus depressive disorders constituted all the cases. Among depressive disorders with impairment, major depressive disorder (MDD) (prevalence of 1.06%) was the most common, followed by dysthymia (prevalence of 0.2%), adjustment disorder with depressive features (prevalence of 0.17%), and depressive disorder-NOS (prevalence of 0.14%). There were no statistically significant gender differences for depression. Maternal psychopathology and paternal physical illness were predictors of affective disorders with pervasive impairment. Conclusion: MDD was the most common depressive disorder among Turkish children in this nationwide epidemiological study. This highlights the severe nature of depression and the importance of early interventions. Populations with maternal psychopathology and paternal physical illness may be the most appropriate targets for interventions to prevent and treat depression in children and adolescents. © 2018
  • No Thumbnail Available
    Item
    COVID-19: vaccination vs. hospitalization
    (Springer Science and Business Media Deutschland GmbH, 2022) Uzun O.; Akpolat T.; Varol A.; Turan S.; Bektas S.G.; Cetinkaya P.D.; Dursun M.; Bakan N.; Ketencioglu B.B.; Bayrak M.; Baris S.A.; Guner R.; Gunal O.; Nural S.; Deniz P.P.; Toprak O.B.; Ozkan G.; Gumus A.; Kerget F.; Ercelik M.; Ataoglu O.; Yuksel A.; Ates G.; Kutsoylu O.E.; Kose N.; Kizilirmak D.; Keskin S.; Gultekin O.; Coskun N.; Yilmaz E.S.; Uslu S.; Basyigit İ.; Ergan B.; Deveci F.; Yakar M.N.; Zuhur C.; Sagcan G.; Yuce Z.T.; Kuluozturk M.; Sezgin M.E.; Sezgin E.N.A.; Havlucu Y.; Cuhadaroglu C.; Kilinc O.; Boyaci H.; Altunay H.; Akti M.; Dursun Z.B.; Kalem A.K.; Isik S.A.; Akyildiz L.; Aykac N.; Almaz M.S.; Kokturk N.; Itil O.
    Objective: Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols. Setting: Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose. Methods: We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status. Results: We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac. Conclusion: Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
  • No Thumbnail Available
    Item
    COVID-19: booster(s) vs. hospitalization and Intensive Care Unit admission
    (Verduci Editore s.r.l, 2023) Toprak O.B.; Akpolat T.; Uzun O.; Pinar Deniz P.; Kokturk N.; Varol A.; Guzel E.; Ercelik M.; Gultekin O.; Guner R.; Turan S.; Gökbulut Bektaş Ş.; Coskun N.; Bakan N.; Nuri Yakar M.; Eren Kutsoylu O.; Ergan B.; Argun Bariş S.; Başyiğit İ.; Boyaci H.; Çetinkaya F.; Çolak H.; Aykac N.; Baran Ketencioğlu B.; Türe Yüce Z.; Akkaya Isik S.; Serap Yilmaz E.; Karaoğlanoğlu S.; Berik Safci S.; Ozkan G.; Kose N.; Kizilirmak D.; Havlucu Y.; Nural S.; Kerget F.; Sunal Ö.; Yuksel A.; Bestepe Dursun Z.; Deveci F.; Kuluozturk M.; Ataoglu O.; Dursun M.; Keskin S.; Emin Sezgin M.; Aktepe Sezgin E.N.; Eser F.; Akyildiz L.; Selim Almaz M.; Kayaaslan B.; Hasanoğlu İ.; Bayrak M.; Gümüş A.; Sağcan G.; Cuhadaroglu C.; Kucuk H.; Onyilmaz T.; Mete B.; Kilinc O.; Oya Itil B.
    OBJECTIVE: As the pandemic continues, different vaccine protocols have been implemented to maintain the protection of vaccines and to provide protection against new variants. The aim of this study was to assess hospitalized patients' vaccination status and document the efficacy of boosters. PATIENTS AND METHODS: The patients that were hospitalized due to COVID-19 were enrolled from 28 hospitals in Turkey for five months from September 2021. 5,331 confirmed COVID-19 patients from collaborating centers were randomly enrolled to understand/estimate the distribution of vaccination status in hospitalized patients and to compare the efficacy of vaccination/booster protocols. RESULTS: 2,779 men and 2,552 women of which 2,408 (45.2%) were admitted to Intensive Care Units participated in this study. It was found that the highest risk reduction for all age groups was found in groups that received 4 doses. Four doses of vaccination for every 3.7 people under 50 years of age, for every 5.7 people in the 50-64 age group, and for every 4.3 people over 65 years of age will prevent 1 patient from being admitted to intensive care. Regardless of the type of vaccine, it was found that the risk of ICU hospitalization decreased in those who were vaccinated compared to those who were not vaccinated. Regardless of the type of vaccine, the ICU risk was found to decrease 1.25-fold in those who received 1 or 2 doses of vaccine, 1.18-fold in those who received 3 doses, and 3.26-fold in those who received 4 doses. CONCLUSIONS: The results suggested that the addition of a fourth dose is more effective in preventing intensive unit care even in disadvantaged. © 2023 Verduci Editore s.r.l. All rights reserved.